Skip to main content

Effectiveness of Cyclophosphamide Pulse Treatment in Wegener’s Granulomatosis

  • Chapter
ANCA-Associated Vasculitides

Summary

43 patients with Wegener’s granulomatosis were studied to evaluate the effectiveness of cyclophosphamide (cyc) pulse treatment. 42% of the patients showed benefits from treatment for at least 6 months after the cessation of cyc pulses. Analysis of clinical and laboratory parameters indicate that this treatment is less effective in patients in whom more than 4 organ systems are involved. Responders to the treatment showed disease manifestations predominantly in the ENT and lower respiratory tract and had lower cANCA titers ( < 1:64) prior to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • De Vita, S., Neri, R., and Bombardieri, S., 1991, Cyclophosphamide pulses in the treatment of rheumatic diseases: an update, Cin.Exp.Rheumatol 9: 179.

    Google Scholar 

  • Haubitz, M., Frei, U., Rother, U., Brunkhorst, R., and Koch, K.M., 1991, Cyclophosphamide pulse therapy in Wegener’s granulomatosis, NephrolDial Transplant. 6: 531.

    Google Scholar 

  • Hoffman, G.S., Kerr, G.S., Leavitt, R.Y., Hallahan, C.W., Lebovics, R.S., Travis, W.D., Rottem, M., and Fauci, A.S., 1992, Wegener granulomatosis: An analysis of 158 patients, Ann.Intern.Med. 116: 488.

    Article  PubMed  CAS  Google Scholar 

  • Hoffman, G.S., Leavitt, R.Y., Fleisher, T.A., Minor, J.R., and Fauci, A.S., 1990, Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide, Am.J.Med. 89: 403.

    Article  PubMed  CAS  Google Scholar 

  • Schmitt, W.H., Heesen, C., Csernok, E., Rautmann, A., and Gross, W.L., 1992, Elevated serum levels of soluble interleukin-2 receptor (sIL-2R) in Wegener’s granulomatosis (WG): Association with disease activity, Arthritis Rheum. 35: 1088.

    Article  PubMed  CAS  Google Scholar 

  • Steppat, D. and Gross, W.L., 1989, Stage-adapted treatment of Wegener’s granulomatosis, Klin. Wochenschr. 67: 666.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Reinhold-Keller, E., Kekow, J., Schnabel, A., Schwarz-Eywill, M., Schmitt, W.H., Gross, W.L. (1993). Effectiveness of Cyclophosphamide Pulse Treatment in Wegener’s Granulomatosis. In: Gross, W.L. (eds) ANCA-Associated Vasculitides. Advances in Experimental Medicine and Biology, vol 336. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9182-2_87

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-9182-2_87

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-9184-6

  • Online ISBN: 978-1-4757-9182-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics